BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 18950764)

  • 1. Patient predictors of histopathologic response after photodynamic therapy of Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
    Yachimski P; Puricelli WP; Nishioka NS
    Gastrointest Endosc; 2009 Feb; 69(2):205-12. PubMed ID: 18950764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer.
    Foroulis CN; Thorpe JA
    Eur J Cardiothorac Surg; 2006 Jan; 29(1):30-4. PubMed ID: 16337389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term efficacy of Photodynamic Therapy (PDT) as an ablative therapy of high grade dysplasia in Barrett's oesophagus.
    Gray J; Fullarton GM
    Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):561-5. PubMed ID: 24284112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Barrett's esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomy.
    Schembre DB; Huang JL; Lin OS; Cantone N; Low DE
    Gastrointest Endosc; 2008 Apr; 67(4):595-601. PubMed ID: 18279860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
    Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study.
    Ortner M-; Zumbusch K; Liebetruth J; Ebert B; Fleige B; Dietel M; Lochs H
    Endoscopy; 2002 Aug; 34(8):611-6. PubMed ID: 12173080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus.
    Small AJ; Sutherland SE; Hightower JS; Guarner-Argente C; Furth EE; Kochman ML; Forde KA; Bewtra M; Falk GW; Ginsberg GG
    Gastrointest Endosc; 2015 May; 81(5):1158-66.e1-4. PubMed ID: 25650071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
    Yachimski P; Mino-Kenudson M; Sherwood ME; Puricelli WP; Nishioka NS; Lauwers GY
    Virchows Arch; 2011 Dec; 459(6):581-6. PubMed ID: 22081106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma.
    Larghi A; Lightdale CJ; Ross AS; Fedi P; Hart J; Rotterdam H; Noffsinger A; Memeo L; Bhagat G; Waxman I
    Endoscopy; 2007 Dec; 39(12):1086-91. PubMed ID: 17701854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient predictors of esophageal stricture development after photodynamic therapy.
    Yachimski P; Puricelli WP; Nishioka NS
    Clin Gastroenterol Hepatol; 2008 Mar; 6(3):302-8. PubMed ID: 18255349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porfimer sodium photodynamic therapy for management of Barrett's esophagus with high-grade dysplasia.
    Panjehpour M; Overholt BF
    Lasers Surg Med; 2006 Jun; 38(5):390-5. PubMed ID: 16788927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients.
    Dumot JA; Vargo JJ; Falk GW; Frey L; Lopez R; Rice TW
    Gastrointest Endosc; 2009 Oct; 70(4):635-44. PubMed ID: 19559428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.
    Overholt BF; Wang KK; Burdick JS; Lightdale CJ; Kimmey M; Nava HR; Sivak MV; Nishioka N; Barr H; Marcon N; Pedrosa M; Bronner MP; Grace M; Depot M;
    Gastrointest Endosc; 2007 Sep; 66(3):460-8. PubMed ID: 17643436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study on light dosimetry variables for photodynamic therapy of Barrett's esophagus with high-grade dysplasia.
    Gill KR; Wolfsen HC; Preyer NW; Scott MV; Gross SA; Wallace MB; Jones LR
    Clin Cancer Res; 2009 Mar; 15(5):1830-6. PubMed ID: 19240171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett's esophagus.
    Ban S; Mino M; Nishioka NS; Puricelli W; Zukerberg LR; Shimizu M; Lauwers GY
    Am J Surg Pathol; 2004 Nov; 28(11):1466-73. PubMed ID: 15489650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.
    Overholt BF; Lightdale CJ; Wang KK; Canto MI; Burdick S; Haggitt RC; Bronner MP; Taylor SL; Grace MG; Depot M;
    Gastrointest Endosc; 2005 Oct; 62(4):488-98. PubMed ID: 16185958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication.
    Guarner-Argente C; Buoncristiano T; Furth EE; Falk GW; Ginsberg GG
    Gastrointest Endosc; 2013 Feb; 77(2):190-9. PubMed ID: 23317687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of Barrett's high-grade dysplasia.
    Weston AP; Sharma P; Topalovski M; Richards R; Cherian R; Dixon A
    Am J Gastroenterol; 2000 Aug; 95(8):1888-93. PubMed ID: 10950031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.